Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 54 of the 55 references it cites were found in a registry or an index; 15 of the 26 sources its claims cite were checked for support.

Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis

Open access

Abstract

Background: It is estimated that over 111,000 people in the U.S. died from a drug overdose in the twelve-month period ending in July 2023. More than three-quarters of those deaths were attributed to opioids. Naloxone has long been available in healthcare facilities to reverse opioid overdose rapidly and safely but is not universally accessible for use in community settings where overdoses occur. We conducted a systematic literature review and meta-analysis to assess the effectiveness of overdose education and naloxone distribution (OEND) programs in three types of community settings to reduce overdose deaths among people who use opioids nonmedically. Methods: We systematically searched electronic databases, including Medline (OVID), Embase (OVID), Psycinfo (OVID), and Global Health (OVID), for peer-reviewed studies of OEND programs published during 2003–2018 (Group 1) that reported overdose outcomes individual level survivals or deaths immediately following naloxone administration. The PRISMA checklist guided screening, quality assessment, and data abstraction. We later identified studies published during 2018–2022 (Group 2), when drug usage and fentanyl-related overdose deaths notably increased, differed from earlier ones. We conducted meta-analyses on both Groups using random effects models to estimate summary survival proportions. Results: Among the 44 Group 1 studies published during 2003–2018, survival did not differ by time (year), location, naloxone dose, or route of administration, but studies of OEND programs serving people who use drugs reported 98.3% (95% CI: 97.5–98.8) survival; those serving family of people who use drugs or other community members reported 95.0% (95% CI: 91.4–97.1) survival; and those for police reported 92.4% (95% CI: 88.9–94.8) survival ( p < 0.01). Five Group 2 studies (2018–2022) yielded similar results. Conclusions: Community-based naloxone distribution programs can be effective in preventing opioid overdose deaths. The paper demonstrates that in the face of increasing overdose deaths over time, survival after naloxone administration has been sustained. The very high survival rates provide clear evidence for public health to continue efforts to expand channels for naloxone distribution in community settings.

Overview

CoChat Summary

## TL;DR

This systematic review and meta-analysis found that community naloxone distribution programs were associated with very high immediate survival after overdose, including in updated studies from 2018–2022. The paper concludes that community-based naloxone distribution can prevent opioid overdose deaths and should be expanded.

## Key findings

  • In 41 Group 1 studies (2003–2018), 74,114 participants reported outcomes after 10,328 naloxone administrations.
  • Random-effects meta-analysis found overall survival of 97.3% (95% CI 96.1–98.3) in Group 1; subgroup survival was 98.3% for programs serving people who use drugs, 95.0% for family/community members, and 92.4% for police.
  • In 5 Group 2 studies (2018–2022), survival was 96.0% (95% CI 94–97), with very little heterogeneity (I² = 3%, p = 0.39).
  • Community-level studies also suggested benefit: one Chicago program reported a 30% reduction in deaths after implementation, Massachusetts saw 27% and 46% reductions in opioid overdose mortality in low- and high-implementing communities versus no implementation, and Scotland reported a 36% reduction in opioid-related deaths among prisoners in the 4 weeks after release.

## Methods

  • Systematic review and meta-analysis of peer-reviewed English-language studies of community-based overdose education and naloxone distribution (OEND) programs in the U.S., Canada, Australia, and Europe.
  • Two search periods were analyzed: 2003–2018 (Group 1) using multiple databases, and 2018–2022 (Group 2) using PubMed; no protocol was registered.
  • Primary outcome was immediate survival or death after naloxone administration; survival proportions were pooled with random-effects models, and study quality was assessed for Group 1 only.

## Limitations

  • The paper states that follow-up was low in many studies, so overdose event outcomes were likely underestimated; this is a stated limitation.
  • The authors note possible publication or small-study bias, though funnel/trim-and-fill analyses found little evidence of it; they also did not review unpublished reports. The text makes these limitations evident.
  • Many evaluations were not independent, often involving people running the programs or collaborating with them. The paper states this limitation.
  • The review could not determine how many overdoses would have been fatal without OEND because most studies had no comparison groups; the text makes this limitation evident.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s12889-025-22210-8

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 PRISMA flow diagram of study selection process for systematic review covering two time periods: 2003–2018 and 2018–2022
Fig. 1 PRISMA flow diagram of study selection process for systematic review covering two time periods: 2003–2018 and 2018–2022CC BY · PubMed Central
Fig. 2 Forest plot of studies of naloxone distribution programs with individual-level survival data: Group 1 (2003-2018) and Group 2 (2018-2022). *Note: ‘Group’ refers to ‘study sample distributed naloxone’
Fig. 2 Forest plot of studies of naloxone distribution programs with individual-level survival data: Group 1 (2003-2018) and Group 2 (2018-2022). *Note: ‘Group’ refers to ‘study sample distributed naloxone’CC BY · PubMed Central

Verification

Claims the paper makes

11 Valid · 0 Not valid · 5 Not checked · 23 Own results and interpretations

18 more claims · 1 with their cited sources checked

Create a free account to see all 39 claims and to verify the 1 reference still open.

See all claims — free account
  • It may state two separate claims as one. 12
  • Probably not a substantial claim. 5

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 55 references

Research works printed but not linked: 3

  1. Szalavitz M. Undoing overdose. Undoing drugs: the untold story of harm reduction and the future of addiction. New York, NY: Hachette Books. 2021;161–72.
  2. Dasgupta N. “Catch up on what’s happening with the naloxone shortage. [Infographic].” Nov 3, 2021, 11:06 AM. Tweet. https://twitter.com/nabarund/status/1455914223641497610
  3. Harm Reduction Therapeutics (HRT). FDA approval of RiVIVE™ is a critical milestone in making emergency treatment of opioid overdose more widely available (Press Release). 28 July 2023. https://www.harmreductiontherapeutics.org/wp-content/uploads/2023/08/HRT-RiVive-Press-Release-July-28-FINAL_DATED.pdf

Cited by

See all 59

Metadata

Authors
Fischer, L. S., Asher, A., Stein, R., Becasen, J., Doreson, A., Mermin, J., Meltzer, M. I., & Edlin, B. R.
Affiliations
  • National Center for Emerging and Zoonotic Infectious Diseases (US)
  • National Center for Injury Prevention and Control (US)
  • National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
  • Substance Abuse and Mental Health Services Administration (US)
Corresponding author
Fischer, Leah S.
Venue
BMC Public Health
Published
2025-03-25
Volume
25
Issue
1
Pages
1135-1135
ISSN
1471-2458 (ISSN-L)
OpenAlex
W4408828505
Cited by
59
References
55
Citations by year
2026: 49 · 2025: 10
FWCI
11.21
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Public Health (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
  • Health Sciences › Medicine › Epidemiology › HIV, Drug Use, Sexual Risk
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords
naloxone distribution, overdose education and naloxone distribution, opioid overdose deaths, drug users, fentanyl overdose, harm reduction services, overdose prevention
MeSH terms
Opiate Overdose, Humans, Naloxone, Narcotic Antagonists, Drug Overdose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1186/s12889-025-22210-8
The paper
Fischer, L. S., Asher, A., Stein, R., Becasen, J., Doreson, A., Mermin, J., Meltzer, M. I., & Edlin, B. R. (2025). Effectiveness of naloxone distribution in community settings to reduce opioid overdose deaths among people who use drugs: a systematic review and meta-analysis. BMC Public Health. https://doi.org/10.1186/s12889-025-22210-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.